HRP20110139T1 - Farmaceutski pripravak koji ima antipsihotičku, antidepresivnu ili antiepileptičku aktivnost sa smanjenim nuspojavama - Google Patents
Farmaceutski pripravak koji ima antipsihotičku, antidepresivnu ili antiepileptičku aktivnost sa smanjenim nuspojavama Download PDFInfo
- Publication number
- HRP20110139T1 HRP20110139T1 HR20110139T HRP20110139T HRP20110139T1 HR P20110139 T1 HRP20110139 T1 HR P20110139T1 HR 20110139 T HR20110139 T HR 20110139T HR P20110139 T HRP20110139 T HR P20110139T HR P20110139 T1 HRP20110139 T1 HR P20110139T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- acid addition
- pharmaceutical preparation
- acceptable acid
- antipsychotic
- Prior art date
Links
- 230000000561 anti-psychotic effect Effects 0.000 title claims abstract 6
- 239000000935 antidepressant agent Substances 0.000 title claims abstract 6
- 230000001430 anti-depressive effect Effects 0.000 title claims 4
- 229940005513 antidepressants Drugs 0.000 title claims 4
- 230000000694 effects Effects 0.000 title claims 3
- 230000003556 anti-epileptic effect Effects 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000002253 acid Substances 0.000 claims abstract 9
- 150000003839 salts Chemical class 0.000 claims abstract 9
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 claims abstract 7
- 239000001961 anticonvulsive agent Substances 0.000 claims abstract 4
- 208000008589 Obesity Diseases 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 235000020824 obesity Nutrition 0.000 claims abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 8
- 229960004170 clozapine Drugs 0.000 claims 3
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims 3
- 229960005017 olanzapine Drugs 0.000 claims 3
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 3
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 3
- 229960001534 risperidone Drugs 0.000 claims 3
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 claims 2
- 239000000164 antipsychotic agent Substances 0.000 claims 2
- 229960004431 quetiapine Drugs 0.000 claims 2
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 2
- 229960004940 sulpiride Drugs 0.000 claims 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical group C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229960001653 citalopram Drugs 0.000 claims 1
- 229960004606 clomipramine Drugs 0.000 claims 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 1
- 229960002464 fluoxetine Drugs 0.000 claims 1
- 229960004038 fluvoxamine Drugs 0.000 claims 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 1
- 159000000011 group IA salts Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960002296 paroxetine Drugs 0.000 claims 1
- 229960002073 sertraline Drugs 0.000 claims 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical group [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims 1
- 229960000604 valproic acid Drugs 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- ISGGVCWFTPTHIX-UHFFFAOYSA-N n'-(2-hydroxy-3-piperidin-1-ylpropoxy)pyridine-3-carboximidamide;dihydrochloride Chemical compound Cl.Cl.C1CCCCN1CC(O)CONC(=N)C1=CC=CN=C1 ISGGVCWFTPTHIX-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Abstract
Upotreba O-(3-piperidino-2-hidroksi-1-propil)-nikotinskog amidoksima ili njegove farmaceutski prihvatljive kisele adicijske soli naznačena time da je za dobivanje farmaceutskog pripravka za sprječavanje ili smanjivanje nuspojava koje dovode do prekomjerne tjelesne težine ili debljine kod liječenja sa poznatim antipsihotičkim, antidepresivnim ili antiepileptičkim lijekovima. Patent sadrži još 9 patentnih zahtjeva.
Claims (10)
1. Upotreba O-(3-piperidino-2-hidroksi-1-propil)-nikotinskog amidoksima ili njegove farmaceutski prihvatljive kisele adicijske soli naznačena time da je za dobivanje farmaceutskog pripravka za sprječavanje ili smanjivanje nuspojava koje dovode do prekomjerne tjelesne težine ili debljine kod liječenja sa poznatim antipsihotičkim, antidepresivnim ili antiepileptičkim lijekovima.
2. Upotreba prema zahtjevu 1 naznačena time da se daje O-(3-piperidino-2-hidroksi-1-propil)- nikotinski amidoksim dihidroklorid.
3. Upotreba prema zahtjevu 1 naznačena time da je antipsihotički lijek odabran od olanzapina, klozapina, risperidona, kvetiapina i sulpirida ili njihovih farmaceutski prihvatljivih kiselih adicijskih soli.
4. Farmaceutski pripravak koji ima antipsihotičku, antidepresivnu ili antiepileptičku aktivnost sa smanjenim nuspojavama koji sadrži poznato antipsihotičko ili antidepresivno ili antiepileptičko sredstvo i O-(3-piperidino-2-hidroksi-1-propil)-nikotinski amidoksim ili njegove farmaceutski prihvatljive kisele adicijske soli u smjesi s jednim ili više uobičajenih nosača.
5. Farmaceutski pripravak prema zahtjevu 4 naznačen time da je antipsihotičko sredstvo odabrano od olanzapina, klozapina, risperidona, kvetiapina i sulpirida ili njihovih farmaceutski prihvatljivih kiselih adicijskih soli.
6. Farmaceutski pripravak prema zahtjevu 4 ili 5 naznačen time da sadrži olanzapin i O-(3-piperidino-2-hidroksi-1-propil)-nikotinski amidoksim ili njegovu farmaceutski prihvatljivu kiselu adicijsku sol.
7. Farmaceutski pripravak prema zahtjevu 4 ili 5 naznačen time da sadrži klozapin i O-(3-piperidino-2-hidroksi-1-propil)-nikotinski amidoksim ili njegovu farmaceutski prihvatljivu kiselu adicijsku sol.
8. Farmaceutski pripravak prema zahtjevu 4 ili 5 naznačen time da sadrži risperidon i O-(3-piperidino-2-hidroksi-1-propil)-nikotinski amidoksim ili njegovu farmaceutski prihvatljivu kiselu adicijsku sol.
9. Farmaceutski pripravak prema zahtjevu 4 naznačen time da je antidepresivno sredstvo odabrano od klomipramina, citaloprama, fluoksetina, fluvoksamina, paroksetina i sertralina ili njihovih farmaceutski prihvatljivih kiselih adicijskih soli.
10. Farmaceutski pripravak prema zahtjevu 4 naznačen time da je antiepileptičko sredstvo valproična kiselina ili njezina farmaceutski prihvatljiva alkalna sol.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85617706P | 2006-11-02 | 2006-11-02 | |
| US11/687,954 US20080108602A1 (en) | 2006-11-02 | 2007-03-19 | Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication |
| PCT/HU2007/000067 WO2008053257A1 (en) | 2006-11-02 | 2007-07-23 | A pharmaceutical composition having antipsychotic, antidepressant or antiepiieptic activity with reduced side effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110139T1 true HRP20110139T1 (hr) | 2011-04-30 |
Family
ID=38595981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110139T HRP20110139T1 (hr) | 2006-11-02 | 2011-02-24 | Farmaceutski pripravak koji ima antipsihotičku, antidepresivnu ili antiepileptičku aktivnost sa smanjenim nuspojavama |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20080108602A1 (hr) |
| EP (1) | EP2089032B1 (hr) |
| JP (1) | JP2010509200A (hr) |
| KR (1) | KR20090077973A (hr) |
| AT (1) | ATE491452T1 (hr) |
| AU (1) | AU2007315932A1 (hr) |
| BR (1) | BRPI0717868A2 (hr) |
| CA (1) | CA2668384A1 (hr) |
| DE (1) | DE602007011316D1 (hr) |
| DK (1) | DK2089032T3 (hr) |
| HK (1) | HK1131736A1 (hr) |
| HR (1) | HRP20110139T1 (hr) |
| IL (1) | IL198294A (hr) |
| MX (1) | MX2009004579A (hr) |
| NO (1) | NO20092024L (hr) |
| PL (1) | PL2089032T3 (hr) |
| PT (1) | PT2089032E (hr) |
| RU (1) | RU2440116C2 (hr) |
| SI (1) | SI2089032T1 (hr) |
| WO (1) | WO2008053257A1 (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090281143A1 (en) * | 2007-12-10 | 2009-11-12 | N-Gene Research Laboratories, Inc. | Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity |
| HUP1100445A2 (en) | 2011-08-17 | 2013-02-28 | Pharma Gene Sa | Pharmaceutical composition |
| HUP1100444A2 (en) | 2011-08-17 | 2013-02-28 | Pharma Gene Sa | Pharmaceutical composition |
| WO2020006367A1 (en) * | 2018-06-29 | 2020-01-02 | Tufts Medical Center, Inc. | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions |
| HUP1800298A1 (hu) | 2018-08-30 | 2020-05-28 | N Gene Res Laboratories Inc | Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4187220A (en) * | 1977-08-30 | 1980-02-05 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. | New O-(3-amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same |
| HU9502843D0 (en) * | 1995-09-29 | 1995-11-28 | Livigene Ltd | Pharmaceutical composition |
| US6884424B2 (en) * | 1995-12-22 | 2005-04-26 | N-Gene Research Laboratories Inc. | Method for treating the pathological lesions of the skin that develop by ultraviolet radiation of the sunlight |
| US6458371B1 (en) * | 1995-12-22 | 2002-10-01 | Medgene, Limited | Cosmetic composition and a method for the prevention and/or reduction of the photoaging processes of the skin |
| HUP9701080A3 (en) * | 1997-06-23 | 1999-05-28 | Gene Res Lab Inc New York N | Pharmaceutical composition containing a compound of antiviral activity and a hydroximic acid ester derivative |
| HU9701081D0 (en) * | 1997-06-23 | 1997-08-28 | Gene Research Lab Inc N | Pharmaceutical composition of antitumoral activity |
| ATE386523T1 (de) * | 2001-07-17 | 2008-03-15 | N Gene Res Lab Inc | Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes |
| US6831077B2 (en) * | 2002-07-25 | 2004-12-14 | Comprehensive Neuroscience, Inc. | Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation |
| HUP0401177A2 (en) * | 2004-06-14 | 2007-09-28 | N Gene Res Lab Inc | Pharmaceutical composition for increasing the mitochondrial genesis |
-
2007
- 2007-03-19 US US11/687,954 patent/US20080108602A1/en not_active Abandoned
- 2007-07-23 CA CA002668384A patent/CA2668384A1/en not_active Abandoned
- 2007-07-23 WO PCT/HU2007/000067 patent/WO2008053257A1/en active Application Filing
- 2007-07-23 KR KR1020097011078A patent/KR20090077973A/ko not_active Application Discontinuation
- 2007-07-23 JP JP2009535138A patent/JP2010509200A/ja active Pending
- 2007-07-23 SI SI200730539T patent/SI2089032T1/sl unknown
- 2007-07-23 PL PL07766499T patent/PL2089032T3/pl unknown
- 2007-07-23 DK DK07766499.3T patent/DK2089032T3/da active
- 2007-07-23 PT PT07766499T patent/PT2089032E/pt unknown
- 2007-07-23 AT AT07766499T patent/ATE491452T1/de active
- 2007-07-23 MX MX2009004579A patent/MX2009004579A/es active IP Right Grant
- 2007-07-23 RU RU2009120115/15A patent/RU2440116C2/ru not_active IP Right Cessation
- 2007-07-23 AU AU2007315932A patent/AU2007315932A1/en not_active Abandoned
- 2007-07-23 EP EP07766499A patent/EP2089032B1/en active Active
- 2007-07-23 BR BRPI0717868-9A2A patent/BRPI0717868A2/pt not_active IP Right Cessation
- 2007-07-23 DE DE602007011316T patent/DE602007011316D1/de active Active
-
2009
- 2009-04-22 IL IL198294A patent/IL198294A/en not_active IP Right Cessation
- 2009-05-25 NO NO20092024A patent/NO20092024L/no not_active Application Discontinuation
- 2009-09-25 HK HK09108840.6A patent/HK1131736A1/xx not_active IP Right Cessation
-
2010
- 2010-08-17 US US12/858,299 patent/US20100311719A1/en not_active Abandoned
-
2011
- 2011-02-24 HR HR20110139T patent/HRP20110139T1/hr unknown
-
2015
- 2015-06-23 US US14/748,150 patent/US20150366852A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2089032A1 (en) | 2009-08-19 |
| CA2668384A1 (en) | 2008-05-08 |
| US20100311719A1 (en) | 2010-12-09 |
| JP2010509200A (ja) | 2010-03-25 |
| AU2007315932A1 (en) | 2008-05-08 |
| EP2089032B1 (en) | 2010-12-15 |
| ATE491452T1 (de) | 2011-01-15 |
| SI2089032T1 (sl) | 2011-04-29 |
| RU2440116C2 (ru) | 2012-01-20 |
| IL198294A0 (en) | 2010-02-17 |
| MX2009004579A (es) | 2009-06-05 |
| HK1131736A1 (en) | 2010-02-05 |
| BRPI0717868A2 (pt) | 2013-10-29 |
| IL198294A (en) | 2011-09-27 |
| KR20090077973A (ko) | 2009-07-16 |
| WO2008053257A1 (en) | 2008-05-08 |
| US20150366852A1 (en) | 2015-12-24 |
| DK2089032T3 (da) | 2011-03-14 |
| DE602007011316D1 (de) | 2011-01-27 |
| RU2009120115A (ru) | 2010-12-10 |
| PL2089032T3 (pl) | 2011-05-31 |
| NO20092024L (no) | 2009-06-02 |
| US20080108602A1 (en) | 2008-05-08 |
| PT2089032E (pt) | 2011-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110139T1 (hr) | Farmaceutski pripravak koji ima antipsihotičku, antidepresivnu ili antiepileptičku aktivnost sa smanjenim nuspojavama | |
| HRP20171256T1 (hr) | Farmaceutski pripravci karbetocina | |
| AR057422A1 (es) | Uan composicion farmaceutica de liberacion modificada, proceso de preparacion de dicha composicion y metodo para emplear la misma | |
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| RS52577B (en) | ONE-DAY OXYCODON FORMULATIONS | |
| HRP20130007T1 (hr) | Lijeäśenje kognitivnih poremeä†aja pomoä†u (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamida i njegovih farmaceutski prihvatljivih soli | |
| NO20055216D0 (no) | Nye hydroksamater som terapeutiske midler | |
| BR0009043A (pt) | Composto, composição farmacêutica, e, método de tratar uma doença em um animal em que a atividade da cisteìna protease contribui para a patologia e/ou sintomatologia da doença | |
| HRP20050123B8 (hr) | Kompozicija i antivirusna aktivnost supstituiranih azaindoloksooctenih piperazin derivata | |
| BRPI0708038B8 (pt) | derivado de cumarina, composição farmacêutica e agente terapêutico para um distúrbio proliferativo celular | |
| RS52457B (en) | POWDER FORMULATION FOR VALGANCICLOVIR | |
| RS54707B1 (en) | TREATMENT OF CROWN LAKVINIMOD DISEASE | |
| ME02495B (me) | Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda | |
| BR0113331A (pt) | Derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica | |
| DOP2012000124A (es) | Derivados de la cromenona con actividad anti-tumoral | |
| HRP20110058T1 (hr) | 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazin kao spoj sa kombiniranom aktivnošću vezanom za ponovno preuzimanje serotonina i i 5-ht3 i 5ht1a aktivnošću, za liječenje bolova ili rezidualnih simptoma u depresiji vezanih za san i kogniciju | |
| UA90893C2 (ru) | Пероральная дозированная форма производных гемцитабина | |
| HRP20191044T1 (hr) | Oftalmološki pripravci i njihova uporaba | |
| RU2017134002A (ru) | Стабильные композиции тетрагидробиоптерина | |
| ATE534626T1 (de) | Piperazinamidine als antivirale mittel | |
| EA200971087A1 (ru) | Фармацевтические композиции и способ лечения острой мании | |
| RS54050B1 (en) | FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS | |
| HRP20230809T1 (hr) | Liječenje alzheimerove bolesti u određenoj populaciji bolesnika | |
| PE20191240A1 (es) | Formas de administracion farmaceutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios | |
| EE200100104A (et) | 5-HT4 agonisti või antagonisti uus peroraalne ravimvorm |